A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128

Summary

The purpose of this study is to assess the safety and tolerability of BMC128 in combination with nivolumab (a known immunotherapy) in order to investigate if administration of select elements of the intestinal microbiome may serve as a novel and effective means of improving the efficacy of anti-cancer immunotherapies.

Timeline

Start

2022-05-01

Primary completion

2024-05

Completion

2025-11

Drugs

Indications